782 related articles for article (PubMed ID: 19188670)
1. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy.
Allegra CJ; Jessup JM; Somerfield MR; Hamilton SR; Hammond EH; Hayes DF; McAllister PK; Morton RF; Schilsky RL
J Clin Oncol; 2009 Apr; 27(12):2091-6. PubMed ID: 19188670
[TBL] [Abstract][Full Text] [Related]
2. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy.
Keedy VL; Temin S; Somerfield MR; Beasley MB; Johnson DH; McShane LM; Milton DT; Strawn JR; Wakelee HA; Giaccone G
J Clin Oncol; 2011 May; 29(15):2121-7. PubMed ID: 21482992
[TBL] [Abstract][Full Text] [Related]
3. American Society of Clinical Oncology provisional clinical opinion: the integration of palliative care into standard oncology care.
Smith TJ; Temin S; Alesi ER; Abernethy AP; Balboni TA; Basch EM; Ferrell BR; Loscalzo M; Meier DE; Paice JA; Peppercorn JM; Somerfield M; Stovall E; Von Roenn JH
J Clin Oncol; 2012 Mar; 30(8):880-7. PubMed ID: 22312101
[TBL] [Abstract][Full Text] [Related]
4. American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases.
Artz AS; Somerfield MR; Feld JJ; Giusti AF; Kramer BS; Sabichi AL; Zon RT; Wong SL
J Clin Oncol; 2010 Jul; 28(19):3199-202. PubMed ID: 20516452
[TBL] [Abstract][Full Text] [Related]
5. Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015.
Allegra CJ; Rumble RB; Hamilton SR; Mangu PB; Roach N; Hantel A; Schilsky RL
J Clin Oncol; 2016 Jan; 34(2):179-85. PubMed ID: 26438111
[TBL] [Abstract][Full Text] [Related]
6. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
Genet Med; 2013 Jul; 15(7):517-27. PubMed ID: 23429431
[TBL] [Abstract][Full Text] [Related]
7. KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer: An Evidence-Based and Economic Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(25):1-49. PubMed ID: 23074403
[TBL] [Abstract][Full Text] [Related]
8. The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer.
Monzon FA; Ogino S; Hammond ME; Halling KC; Bloom KJ; Nikiforova MN
Arch Pathol Lab Med; 2009 Oct; 133(10):1600-6. PubMed ID: 19792050
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
Tol J; Punt CJ
Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
[TBL] [Abstract][Full Text] [Related]
10. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.
Siena S; Sartore-Bianchi A; Di Nicolantonio F; Balfour J; Bardelli A
J Natl Cancer Inst; 2009 Oct; 101(19):1308-24. PubMed ID: 19738166
[TBL] [Abstract][Full Text] [Related]
11. KRAS p.G13D mutations are associated with sensitivity to anti-EGFR antibody treatment in colorectal cancer cell lines.
Messner I; Cadeddu G; Huckenbeck W; Knowles HJ; Gabbert HE; Baldus SE; Schaefer KL
J Cancer Res Clin Oncol; 2013 Feb; 139(2):201-9. PubMed ID: 23015072
[TBL] [Abstract][Full Text] [Related]
12. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials.
Sorich MJ; Wiese MD; Rowland A; Kichenadasse G; McKinnon RA; Karapetis CS
Ann Oncol; 2015 Jan; 26(1):13-21. PubMed ID: 25115304
[TBL] [Abstract][Full Text] [Related]
13. Systematic review: Anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer.
Dahabreh IJ; Terasawa T; Castaldi PJ; Trikalinos TA
Ann Intern Med; 2011 Jan; 154(1):37-49. PubMed ID: 21200037
[TBL] [Abstract][Full Text] [Related]
14. Japanese Society of Medical Oncology Clinical Guidelines: RAS (KRAS/NRAS) mutation testing in colorectal cancer patients.
Taniguchi H; Yamazaki K; Yoshino T; Muro K; Yatabe Y; Watanabe T; Ebi H; Ochiai A; Baba E; Tsuchihara K;
Cancer Sci; 2015 Mar; 106(3):324-7. PubMed ID: 25800101
[TBL] [Abstract][Full Text] [Related]
15. Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?
Roberts PJ; Stinchcombe TE; Der CJ; Socinski MA
J Clin Oncol; 2010 Nov; 28(31):4769-77. PubMed ID: 20921461
[TBL] [Abstract][Full Text] [Related]
16. The treatment of colorectal carcinoma with monoclonal antibodies: the importance of KRAS mutation analysis and EGFR status.
Stintzing S; Heinemann V; Moosmann N; Hiddemann W; Jung A; Kirchner T
Dtsch Arztebl Int; 2009 Mar; 106(12):202-6. PubMed ID: 19471640
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS.
Kishiki T; Ohnishi H; Masaki T; Ohtsuka K; Ohkura Y; Furuse J; Watanabe T; Sugiyama M
Cancer Chemother Pharmacol; 2014 Apr; 73(4):749-57. PubMed ID: 24500024
[TBL] [Abstract][Full Text] [Related]
18. Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients.
Ruzzo A; Graziano F; Canestrari E; Magnani M
Curr Cancer Drug Targets; 2010 Feb; 10(1):68-79. PubMed ID: 20088793
[TBL] [Abstract][Full Text] [Related]
19. KRAS mutation in colon cancer: a marker of resistance to EGFR-I therapy.
Siddiqui AD; Piperdi B
Ann Surg Oncol; 2010 Apr; 17(4):1168-76. PubMed ID: 19936839
[TBL] [Abstract][Full Text] [Related]
20. Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab.
Peeters M; Douillard JY; Van Cutsem E; Siena S; Zhang K; Williams R; Wiezorek J
J Clin Oncol; 2013 Feb; 31(6):759-65. PubMed ID: 23182985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]